12 citations
,
January 2023 in “Indian Dermatology Online Journal”
This review discusses the diagnostic and therapeutic challenges of hairshaftdisorders and suggests diagnostic tools like trichoscopy and light microscopy, but reports no new clinical results.
This case study reported that in a 67-year-old woman with Netherton syndrome, treatment with dupilumab improved skin inflammation and pruritus and was associated with significant improvements in hair growth and structure, including the resolution of "bamboo" hair.
4 citations
,
January 2016 in “Postepy Dermatologii I Alergologii”
This article discusses various hair diseases and emphasizes their significant impact despite affecting a small area, but does not report new clinical findings.
A permanent hair loss solution could involve reprogramming hair follicles to resist DHT using mRNA and siRNA. However, high costs, safety concerns, and the pharmaceutical industry's preference for ongoing treatments over one-time cures are major obstacles, with finasteride and minoxidil remaining standard treatments.
PP405 is a new hair loss treatment in phase 2 trials that may promote hair growth by increasing lactate production and activating hair follicle stem cells. It could potentially replace hormone-disrupting treatments like Minoxidil and finasteride.
Hair loss treatments like finasteride, minoxidil, and dutasteride work but have side effects. A permanent cure is still not available due to the complexity of hair loss and limited investment.
AI advancements, like AlphaFold, are speeding up drug discovery for hair loss, promising more effective treatments. Current options like minoxidil and finasteride have limitations, but new developments could improve solutions in 5-10 years.
Increased Malassezia and Cutibacterium in the scalp microbiome are linked to higher sebum production and inflammation in androgenetic alopecia (AGA). Treatments include ciclopirox shampoo, benzoyl peroxide shampoo, clobetasol propionate, calcipotriol, minoxidil, finasteride, and dutasteride.